Esperion Therapeutics News

Esperion Therapeutics Analyst Ratings

BenzingaApr 10 06:47 ET

Northland Securities Sticks to Their Hold Rating for Esperion (ESPR)

TipRanksMar 25 08:55 ET

Esperion Therapeutics Analyst Ratings

BenzingaMar 25 07:33 ET

Esperion Therapeutics Analyst Ratings

BenzingaFeb 27 14:46 ET

Esperion Therapeutics Analyst Ratings

BenzingaNov 20, 2023 08:25 ET

Esperion Therapeutics Analyst Ratings

BenzingaNov 13, 2023 11:17 ET

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $8

BenzingaNov 7, 2023 15:29 ET

Esperion Therapeutics Analyst Ratings

BenzingaNov 7, 2023 15:28 ET

Needham Reiterates Buy on Esperion Therapeutics, Maintains $9 Price Target

BenzingaOct 2, 2023 06:31 ET

Esperion Therapeutics Analyst Ratings

BenzingaOct 2, 2023 06:29 ET

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $22 Price Target

BenzingaAug 28, 2023 06:41 ET

Esperion Therapeutics Analyst Ratings

BenzingaAug 28, 2023 06:38 ET

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $9

BenzingaAug 2, 2023 04:11 ET

Esperion Therapeutics Analyst Ratings

BenzingaAug 2, 2023 04:10 ET

Northland Securities Upgrades Esperion Therapeutics to Market Perform From Underperform, Raises Price Target to $2 From $1

MT NewswiresAug 1, 2023 13:57 ET

Esperion Jumps 15% as BofA Double-upgrades Citing Near-term Upside

Seeking AlphaJun 15, 2023 09:12 ET

B of A Securities Upgrades Esperion Therapeutics to Buy, Raises Price Target to $4

BenzingaJun 15, 2023 06:21 ET

Analyst Ratings for Esperion Therapeutics

BenzingaJun 1, 2023 15:02 ET

HC Wainwright & Co. Reiterates Buy on Esperion Therapeutics, Maintains $22 Price Target

BenzingaJun 1, 2023 10:35 ET

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $10

BenzingaMay 9, 2023 12:27 ET